Effects of Rivaroxaban on Renal Function in Non-valvular atrial Fibrillation Patients with Chronic Kidney Diseases

INTERVENTION: rivaroxaban group warfarin group CONDITION: Non‐valvular atrial Fibrillation Patients with Chronic Kidney Diseases PRIMARY OUTCOME: The primary endpoint was the change amount in urinary albumin 3 months after registration. SECONDARY OUTCOME: The secondary endpoints were changes amount in endothelial functions, inflammatory markers, renal function markers, osteocalcin markers. INCLUSION CRITERIA: Inclusion criteria (1)Age>‐ 30 years old. (2)Patients who had initiated anticoagulation therapy or patients who had already received warfarin therapy. (3)estimated glomerular filtration rate > 30 and < 60 mL/min/1.73 m2: CKD grade G2 to G3b.